Company Overview
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Why Investors Should Care
Net profit has compounded at 34.4% per year over the last five years.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR 34.4%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | 34.40% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +34.23% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -27.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)43.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 34.4% over 5 years.
CONS
- Trading 48.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VOGX Vogenx, Inc. PHARMA | 17.45 | -79.32 | $259.22M | 0.00% | - | - | - | 34.40% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 372.20K | 463.15K |
| Operating Income | -372.20K | -463.15K |
| EBITDA | -372.20K | -463.15K |
| Interest Expense | - | - |
| Pretax Income | -356.62K | -475.45K |
| Tax Provision | - | - |
| Net Income | -356.62K | -475.45K |
| Diluted EPS | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 2.30M | 1.44M |
| Operating Income | -2.30M | -1.44M |
| EBITDA | -2.30M | -1.44M |
| Interest Expense | - | - |
| Pretax Income | -2.20M | -1.45M |
| Tax Provision | - | - |
| Net Income | -2.20M | -1.45M |
| Diluted EPS | -0.29 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VOGX
Vogenx, Inc. (VOGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9qU2VtMmJmdTBXX0VaTHJrbmo3NHM4VW9NZnpKcnJoQ215U1hIN005NWhSZzhMRUdNOXpOZ1Ezb1B0d0lla0ZrQWtxYXJELV9oanc?oc=5" target="_blank">Vogenx, Inc. (VOGX) Stock Price, News, Quote & History</…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5vMW96M1RDdW4zTmFWRUxnbDZndmFDeXpiRVluRzdrbGxnQk52WldCek90TWh5amxheEhEMXJOWDA2M3Z5VHpwcXlQaWMxMVdP?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZE0wck5lRzFoNE8yNkI1WlJGTGR1S0VLeHBzYWNfRkJETXdzUmo0ZEZ1WWlFOTl4MG9FLWY0cks3dEpyalRIMllrTDViMXZoUFlXbjJHU0p2Y3VtZ1dzekJ1Q0lmUFhyempzSkx5Nm5Gb0V1MTI3OFJMMkZyQnd4WUZlSmtzZEh5N1Zhd1…
155,000 options for Vogenx (VOGX) science chief vest over three years, subject to continued service. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPWEEzc1lxc3ZwNHFGVk5nNXNlalp4TzZyUkI3enIxQzJnMUVJVEJpTElQTlFlRkg2eG9QblMzNWVrbGlIOGk5dTVxalMzTjhKVDRmLWNYc0I5SHlDM3BXVkF4UDdGc3Vmd3AzWWw4NzJTYVZkRWZJbm9UYW5EbzI0MTlJSDN3aTB5SHcyZ3…
Vogenx surpasses expectations with $81m IPO - pharmaphorum
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE5yQjVuaGJLcXdDZERSWVFxV2p2aUNYTEpaaEZkYmVnVXFBVi1TZ0ZJdWtCMklwdkFsdy1UZ1dTMkdLcWZwU1dSbG81OEZzSXBtUHNkQVl3emRMY09ZcHNFZGtfRVlTV2tFZ1dkT0VlVmxxdTRWZUE?oc=5" target="_blank">Vogenx s…
Vogenx, Inc. (VOGX) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9uOVZFbjk4VEhMV0M3aVA4R3RCMDRwYVBtWXlmTUxBY1NTaFotaXNCZFExaWJkbEdQeWdBTkR4c2RqRG9odHlNT0h1YUg0dllId3c?oc=5" target="_blank">Vogenx, Inc. (VOGX) stock price, news, quote and history…
VOGX — Frequently Asked Questions
What is the current share price of Vogenx, Inc. (VOGX)?
As of 2026-10-23 16:27 PDT, Vogenx, Inc. (VOGX) trades at $17.45 on NasdaqCM. Its 52-week range is $13.00 to $34.13.
What is the market capitalisation of VOGX?
Vogenx, Inc. (VOGX) has a market capitalisation of $259.22M on NasdaqCM.
What is the P/E ratio of VOGX?
VOGX trades at a trailing price-to-earnings (P/E) ratio of -79.32. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -51.95.
Is VOGX a good stock to buy?
This page provides a data-driven analysis of Vogenx, Inc. (VOGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.